“A Day of Results”: Senate Passes Compounding/Track & Trace
This article was originally published in RPM Report
On November 18, the Senate enacted passed H.R. 3204, the Drug Quality and Security Act by a voice vote, and the new pharmacy compounding/supply chain security bill is set to be signed into law. One of the key reasons for that was the support from Senate Health Subcommittee ranking member, Lamar Alexander, whose home state experienced a disproportionate impact from the meningitis outbreak traced back to compounded products. Here are his remarks on the Senate floor immediately after the vote.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.